Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant diseases worldwide and has become a leading cause for cancer-related deaths in adults from Asia and sub-Saharan Africa (1). The DNA tumor virus hepatitis B virus (HBV) has been implicated to play a major causative role in the development of HCC in man (2–4). The HBx gene, the smallest viral openreading frame that may be essential for the viral life cycle (5,6), largely contributes the oncogenecity of HBV. The selective retention and expression of the HBx gene during acute and chronic hepatitis as well as in a great majority of HCCs may constitute an important step during HCC development (7,8). The oncogenic potential of the HBx gene has been experimentally demonstrated in a transgenic mice model (9) and in cell culture systems (10,11). HBx alone can induce HCC in certain transgenic mice (9) or can increase susceptibility to chemical carcinogens (12) and accelerate c-myc-induced HCC (13). Consequently, as an oncoprotein, HBx has been reported to disregulate cell-cycle transition (14,15) to potentially target certain proteases and proteasome (16–18), to interact with DNA repair factors (19,20), or to interact with the p53 tumor suppressor gene product (21–24).
Keywords
- Primary Human Hepatocyte
- Annexin Versus Staining
- Primary Human Fibroblast
- CsCl Density Gradient Centrifugation
- Major Causative Role
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Di Bisceglie, A. M., Rustgi, V. K., Hoofnagle, J. H., Dusheiko, G. M., and Lotze, M. T. (1988) NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108, 390–401.
Beasley, R. P., Hwang, L. Y., Lin, C. C., and Chien, C. S. (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 2, 1129–1133.
Popper, H., Shafritz, D. A., and Hoofnagle, J. H. (1987) Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology. 7, 764–772.
Beasley, R. P. (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 61, 1942–1956.
Chen, H. S., Kaneko, S., Girones, R., Anderson, R. W., Hornbuckle, W. E., Tennant, B. C., et al. (1993) The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 67, 1218–1226.
Zoulim, F., Saputelli, J., and Seeger, C. (1994) Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 68, 2026–2030.
Unsal, H., Yakicier, C., Marcais, C., Kew, M., Volkmann, M., Zentgraf, H., Isselbacher, K. J., and Ozturk, M. (1994) Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci USA 91, 822–826.
Paterlini, P., Poussin, K., Kew, M., Franco, D., and Brechot, C. (1995) Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 21, 313–321.
Kim, C. M., Koike, K., Saito, I., Miyamura, T., and Jay, G. (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 351, 317–320.
Shirakata, Y., Kawada, M., Fujiki, Y., Sano, H., Oda, M., Yaginuma, K., et al. (1989) The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn. J. Cancer Res. 80, 617–621.
Hohne, M., Schaefer, S., Seifer, M., Feitelson, M. A., Paul, D., and Gerlich, W. H. (1990) Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J. 9, 1137–1145.
Slagle, B. L., Lee, T. H., Medina, D., Finegold, M. J., and Butel, J. S. (1996) Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinogen. 15, 261–269.
Terradillos, O., Billet, O., Renard, C. A., Levy, R., Molina, T., Briand, P., et al. (1997) The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene. 14, 395–404.
Koike, K., Moriya, K., Yotsuyanagi, H., Iino, S., and Kurokawa, K. (1994) Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J. Clin. Invest. 94, 44–49.
Benn, J. and Schneider, R. J. (1995) Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl. Acad. Sci USA 92, 11215–11219.
Fischer, M., Runkel, L., and Schaller, H. (1995) HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome alpha-subunit. Virus. Genes, 10, 99–102.
Huang, J., Kwong, J., Sun, E. C., and Liang, T. J. (1996) Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol. 70, 5582–5591.
Sirma, H., Weil, R., Rosmorduc, O., Urban, S., Israel, A., Kremsdorf, D., et al. (1998) Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene. 16, 2051–2063.
Lee, T. H., Elledge, S. J., and Butel, J. S. (1995) Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J. Virol. 69, 1107–1114.
Qadri, I., Conaway, J. W., Conaway, R. C., Schaack, J., and Siddiqui, A. (1996) Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc. Natl. Acad. Sci. USA 93, 10,578–10,583.
Feitelson, M. A., Zhu, M., Duan, L. X., and London, W. T. (1993) Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 8, 1109–1117.
Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C. (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci USA 91, 2230–2234.
Takada, S., Tsuchida, N., Kobayashi, M., and Koike, K. (1995) Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J. Cancer Res. Clin. Oncol. 121, 593–601.
Truant, R., Antunovic, J., Greenblatt, J., Prives, C., and Cromlish, J. A. (1995) Direct inhibition of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol. 69, 1851–1859.
Siddiqui, A., Jameel, S., and Mapoles, J. (1987) Expression of the hepatitis B virus X gene in mammalian cells. Proc. Natl. Acad. Sci USA 84, 2513–2517.
Twu, J. S. and Schloemer, R. H. (1987) Transcriptional trans-activating function of hepatitis B virus. J. Virol. 61, 3448–3453.
Spandau, D. F. and Lee, C. H. (1988) trans-activation of viral enhancers by the hepatitis B virus X protein. J. Virol. 62, 427–434.
Seto, E., Yen, T. S., Peterlin, B. M., and Ou, J. H. (1988) Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc. Natl. Acad. Sci USA 85, 8286–8290.
Twu, J. S., Chu, K., and Robinson, W. S. (1989) Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA, 86, 5168–5172.
Colgrove, R., Simon, G., and Ganem, D. (1989) Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J. Virol. 63, 4019–4026.
Twu, J. S. and Robinson, W. S. (1989) Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc. Natl. Acad. Sci. USA, 86, 2046–2050.
Levrero, M., Balsano, C., Natoli, G., Avantaggiati, M. L., and Elfassi, E. (1990) Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2. J. Virol. 64, 3082–3086.
Lucito, R. and Schneider, R. J. (1992) Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J. Virol. 66, 983–991.
Aufiero, B. and Schneider, R. J. (1990) The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters. EMBO J. 9, 497–504.
Cross, J. C., Wen, P., and Rutter, W. J. (1993) Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/ threonine kinases. Proc. Natl. Acad. Sci USA 90, 8078–8082.
Twu, J. S., Lai, M. Y., Chen, D. S., and Robinson, W. S. (1993) Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology. 192, 346–350.
Luber, B., Lauer, U., Weiss, L., Hohne, M., Hofschneider, P. H., and Kekule, A. S. (1993) The hepatitis B virus transactivator HBx causes elevation of diacylglycerol and activation of protein kinase C. Res. Virol. 144, 311–321.
Natoli, G., Avantaggiati, M. L., Chirillo, P., Costanzo, A., Artini, M., Balsano, C., et al. (1994) Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol. Cell Biol, 14, 989–998.
Doria, M., Klein, N., Lucito, R., and Schneider, R. J. (1995) The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 14, 4747–4757.
Williams, J. S. and Andrisani, O. M. (1995) The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB. Proc. Natl. Acad. Sci USA 92, 3819–3823.
Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J. 14, 143–150.
Qadri, I., Maguire, H. F., and Siddiqui, A. (1995) Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc. Natl. Acad. Sci USA 92, 1003–1007.
Kekulë, A. S., Lauer, U., Weiss, L., Luber, B., and Hofschneider, P. H. (1993) Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature. 361, 742–745.
Benn, J. and Schneider, R. J. (1994) Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl. Acad. Sci. USA, 91, 10,350–10,354.
Wang, H. D., Trivedi, A., and Johnson, D. L. (1997) Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signaling pathway. Mol. Cell. Biol. 17, 6838–6846.
Chirillo, P., Pagano, S., Natoli, G., Puri, P. L., Burgio, V. L., Balsano, C., et al. (1997) The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc. Natl. Acad. Sci USA 94, 8162–8167.
Kim, H., Lee, H., and Yun, Y. (1998) X-gene product of hepatitis B virus induces apoptosis in liver cells. J. Biol. Chem, 273, 381–385.
Su, F. and Schneider, R. J. (1997) Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc. Natl. Acad. Sci USA 94, 8744–8749.
Lane, D. P. (1992) Cancer. p53, guardian of the genome. Nature. 358, 15–16.
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell. 71, 587–597.
Lee, S., Elenbase, B., Levine, A., and Griffith, J. (1995) p53 and Its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 81, 1013–1020.
Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., et al.(1995) p53 Modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10, 188–195.
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70, 923–935.
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70, 937–948.
Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352, 345–347.
Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci USA 89, 4495–4499.
Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26, 239–257.
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362, 849–852.
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362, 847–849.
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., et al. (1994) p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78, 703–711.
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379, 88–91.
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991) p53 Mutations in human cancers. Science. 253, 49–53.
Levine, A. J., Momand, J., and Finlay, C. A. (1991) The p53 tumour suppressor gene. Nature. 351, 453–456.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878.
Lee, J. M. and Bernstein, A. (1993) p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90, 5742–5746.
Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993) p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74, 957–967.
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., et al. (1994) p53 Status and the efficacy of cancer therapy in vivo. Science. 266, 807–810.
Wang, X. W. and Harris, C. C. (1996) TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surveys. 28, 169–196.
Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., et al. (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet. 9, 41–47.
Elmore, L. W., Hancock, A. R., Chang, S. F., Wang, X. W., Chang, S., Callahan, C. P., et al. (1997) Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. USA, 94, 14,707–14,712.
Lin, Y., Nomura, T., Yamashita, T., Dorjsuren, D., Tang, H., and Murakami, S. (1997) The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 57, 5137–5142.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., et al. (1996) The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10, 1219–1232.
Wang, X. W., Gibson, M. K., Vermeulen, W., Yeh, H., Forrester, K., Sturzbecher, H. W., et al. (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 55, 6012–6016.
Takada, S., Kaneniwa, N., Tsuchida, N., and Koike, K. (1996) Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology. 216, 80–89.
Takada, S., Kaneniwa, N., Tsuchida, N., and Koike, K. (1997) Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene. 15, 1895–1901.
Hosono, S., Chou, M. J., Lee, C. S., and Shih, C. (1993) Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 8, 491–496.
Henkler, F., Waseem, N., Golding, M. H., Alison, M. R., and Koshy, R. (1995) Mutant p53 but not Hepatitis B virus X protein is present in Hepatitis B virus-related human hepatocellular carcinoma. Cancer Res. 55, 6084–6091.
Greenblatt, M. S., Feitelson, M. A., Zhu, M., Bennett, W. P., Welsh, J. A., Jones, R., et al. (1997) Integrity of p53 in hepatitis B x antigen-positive and-negative hepatocellular carcinomas. Cancer Res. 57, 426–432.
Huang, L. C., Clarkin, K. C., and Wahl, G. M. (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl. Acad. Sci. USA, 93, 4827–4832.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Wei Wang, X. (2000). Abrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene. In: Habib, N.A. (eds) Hepatocellular Carcinoma. Methods in Molecular Medicine™, vol 45. Humana Press. https://doi.org/10.1385/1-59259-079-9:57
Download citation
DOI: https://doi.org/10.1385/1-59259-079-9:57
Publisher Name: Humana Press
Print ISBN: 978-0-89603-785-4
Online ISBN: 978-1-59259-079-7
eBook Packages: Springer Protocols